PD59-07 RISK FACTORS OF PHARMACOTHERAPY FOR STORAGE SYMPTOMS AFTER TRANSURETHRAL RESECTION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

INTRODUCTION AND OBJECTIVES: Storage symptoms in older men may occur either secondary to or independent from benign prostatic hyperplasia (BPH).Surgical management with transurethral resection of the prostate (TURP) may be indicated in some BPH patients.Pharmacotherapy for storage symptoms may be warranted for those who have storage symptoms not effectively treated by surgery or develop de novo storage symptoms.This study analyzed the risk factors of the use of antimuscarinics or beta-3 agonist after TURP in BPH patients.METHODS: We retrospectively reviewed 391 patients with BPH who underwent TURP between January 2015 and December 2016.All patients received preoperative assessment with International Prostate Symptom Score, uroflowmetry, prostate volume and intravesical prostatic protrusion (IPP).Postoperative pharmacotherapy for storage symptoms was defined as the prescription of antimuscarinics or beta-3 agonist 3 months after TURP for more than 3 months.We evaluated the effects of comorbidities, symptoms severity, results of preoperative evaluation, and TURP-related variables for postoperative prescription of antimuscarinics or beta-3 agonist.RESULTS: Of 391 patients included in this study, 46 (11.8 %) received postoperative pharmacotherapy for storage symptoms after TURP.Patients with postoperative pharmacotherapy were significantly older than those without (77.4Æ7.8 vs 74.4Æ9.9 years, p ¼ 0.024).Patients underwent bipolar TURP tended to use postoperative e1142 THE JOURNAL OF UROLOGY â Vol.199, No. 4S, Supplement,